Clinical studies have implicated human RIPK1 in a wide range of systemic disorders and pathologies [41–46], leading to substantial interest in developing RIPK1 therapeutics, particularly for treating inflammatory diseases and cancer [46–48]. This evidence concerns the gene RIPK1 and cancer.